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Abstract
During the last decade, a new view into themolecular mechanisms of chronic kidney disease-mineral bone disorder (CKD-MBD)
has been proposed, with ﬁbroblast growth factor 23 (FGF23) as a novel player in the ﬁeld. Enhanced serum FGF23 levels cause a
reduction in serum phosphate, together with calcitriol suppression and consequent hyperparathyroidism (HPT). In contrast,
reduced serum FGF23 levels are associated with hyperphosphatemia, higher calcitriol levels and parathyroid hormone (PTH)
suppression. In addition, serum FGF23 levels are greatly increased and positively correlated with serum phosphate levels in CKD
patients. In this population, high serum FGF23 concentration seems to predict the occurrence of refractory secondary HPT and to
be associated with highermortality risk in incident haemodialysis patients. In living-donor kidney transplant recipients, a faster
normalization of FGF23 and phosphate levels with a lower prevalence of HPT, may be considered amajor pathway to investigate.
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Kidney transplantation is the best renal therapy for eligible end-
stage renal disease (ESRD) patients. Kidney transplant recipients
have better survival rates than dialysis patients, with lower dialy-
sis-related morbidity, reduced cardiovascular risk, improved
quality of life and reduced health economic costs [1, 2].
Due to an organ shortage, however,most patients have towait
while on dialysis for a considerable period of time prior to
transplantation, with unfavourable consequences such as com-
promised graft and patient survival. Living-donor kidney trans-
plantation and pre-emptive kidney transplant, deﬁned as
transplant before dialysis, are valid options to expand the organ
pool and reduce the waiting time of patients on the waiting list,
and the short- and long-term outcomes seem to be favourable
compared with deceased-donor kidney transplantation [3]. Ab-
normalities in serum calcium, phosphorus, parathyroid hormone
(PTH), ﬁbroblast growth factor 23 (FGF23) and vitamin D levels
occur early in the course of chronic kidney disease (CKD) to
become a widespread complication in patients with advanced
renal disease [4]. Mineral and bone disorders are common in pa-
tients who have undergone kidney transplantation [5]. Although
for a long time it has been supposed that successful kidney trans-
plantation to a large extent solves the problem of CKD–mineral
and bone disorder (CKD-MBD), mineral and bone disorders are
common inkidney transplant recipients, changing only its pheno-
type. These conditions are caused, to a large extent, by previous
bone damage and CKD-MBD persisting after transplantation, de
novo CKD-MBD and immunosuppressive therapy. The contribu-
tion of each component to the overall scenario changes over time.
In long-term kidney transplant recipients with a well-
functioning graft (eGFR >30–45 mL/min), high PTH levels can
still be observed in 30–60% at 1 year after transplantation [6].
Post-transplant hyperparathyroidism can be differentiated into a
maladaptive response (‘persistent’ hyperparathyroidism) versus a
compensatory–adaptive response (de novo hyperparathyroidism).
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‘Persistent’ hyperparathyroidism results from pre-existing CKD-
MBD with secondary hyperparathyroidism, likely complicating
post-transplant follow-up with hypercalcaemia, hypophospha-
taemia, fracture risk [7], vascular calciﬁcation [8] and loss of
graft function [9]. Conversely, de novo hyperparathyroidism re-
sults in elevated PTH levels, along with deterioration of graft func-
tion, to maintain normophosphataemia and normocalcaemia.
Serum levels of the bone-derived phosphaturic hormone
FGF23 are extremely high in dialysis patients, reaching levels
that can be 1000-fold above the normal range [4, 10], in an at-
tempt to counteract hyperphosphataemia, producing a decrease
of 1,25-dihydroxyvitamin D. Additional triggers for FGF23 in late
CKD are secondary hyperparathyroidism and Klotho deﬁciency.
FGF23 levels decline 3months after transplantation but remain
higher than in CKD patientsmatched for eGFR. Further reductions
in FGF23 levels were repeatedly observed over longer follow-up,
approximating normal levels 1–3 years after transplantation
[6, 11].
In contrast, in a cross-sectional observational study of 279
maintenance kidney recipients with CKD (stages 1–4), Sanchez
Fructuoso et al. [12] found that FGF23 levels increased in long-
term kidney graft recipients, even in the early stages of CKD,
maybe as a result of previous chronic phosphate retention stimu-
lating the secretion of FGF23. These ﬁndings support the notion
of a persistent (or tertiary) hyperphosphatoninism that in the
early post-transplant period mainly reﬂects previous mineral
and bone disorders while in the long termmirrors renal function
that is the major determinant of FGF23 serum levels, similar to
what is observed in CKD patients. The interactions between
FGF23 and PTH are very complex and cause a decrease in vitamin
D metabolism. FGF23 and PTH mutually regulate each other in a
negative feedback loop where PTH stimulates FGF23 production
and FGF23, in turn, suppresses PTH synthesis acting via the
Klotho–FGF receptor 1 (FGFR1) complex in the parathyroid gland
and in the absence of Klotho via a phosphoinositide-speciﬁc
phospholipase C gamma (PLCγ)-dependent activation of the cal-
cineurin–nuclear factor of activated T cells (NFAT) pathway [13].
The mitogen-activated protein kinase (MAPK) pathway is likely
the dominant pathway in physiology, although its relative contri-
bution is unknown.
Hypophosphataemia is present in up to 90% of transplant re-
cipients [14], with the majority (70%) of the cases being mild to
moderate (serum phosphate level >1.5 to <2.3 mg/dL); phosphate
levels remain low for longer than in patients with CKD matched
for the GFR [15]. Acute or chronic post-transplant hypophospha-
taemia may cause detrimental effects. In the early post-trans-
plant period, when serum phosphate levels are lower, muscle
weakness may occur [16], whereas effects of chronic hypopho-
sphataemia are less clear. There are few studies on the parallel
changes in PTH, FGF23 and phosphate levels and mostly detailed
in deceased-donor kidney transplantation with a follow-up of <1
year. Based on the data available, it is estimated that the effect
of these phosphaturic hormones onhypophosphataemia changes
over time after transplantation. FGF23 has emerged as an import-
ant mediator of early hypophosphataemia, and its phosphaturic
effect is enforced by persistent hyperparathyroidism and 1,25-di-
hydroxyvitamin D deﬁciency. In the long term, hypophosphatae-
mia and renal phosphate loss are mainly related to persistent
hyperparathyroidism [17, 18] (Figure 1).
The role of different strategies in the treatment of CKD-MBD
before transplantation is an underestimated issue in the ﬁeld of
mineral and bone disorders in kidney transplant recipients,
which expalins the wide variability reported in the literature. In
particular, kidney transplant recipients undergoing treatment
with cinacalcet before transplantation had high rates of
persistent hyperparathyroidism, hypophosphataemia and hy-
percalcaemia after transplantation [18].
In the ﬁrst year after transplantation, the faster normalization
of FGF23 levels, compared with PTH levels, suggests that FGF23-
producing cells may experience a quick reset of their activities
in response to the recovery of renal function, all despite persist-
ently elevated PTH levels, which stimulates FGF23 production.
The long-lasting PTH-related renal phosphate wasting in kidney
transplant recipients induces a negative phosphate balance that
is appropriately sensed byosteocytes, thus decreasing FGF23 pro-
duction in an effort to conserve phosphate, despite the stimula-
tory effects of high PTH levels.
A fewand heterogeneous studies, andwith a small number of
patients, have analysed the changes in phosphate, PTH and
FGF23 levels in living-donor kidney transplants. In a study of 39
living-donor kidney transplant recipients [19], FGF23 levels at
12 months after kidney transplantation were relatively low [20]
and intact PTH (iPTH) levels were comparably high relative to
the GFR; the pathogenesis of hypophosphataemia at 12 months
may be due largely to persistent hyperparathyroidism rather
than high FGF23 levels. It could also be argued that FGF23 levels
remain inappropriately elevated, especially in light of low serum
phosphorus levels anddecreasedurinary phosphate reabsorption,
which therefore suggests that a dysregulation of the FGF23, renal
phosphate and PTH axis may be present. An interesting ﬁnding
in this study is that the pre-transplant FGF23 level was the best
predictor of hypophosphataemia at 12 months.
These results are in agreement with those observed in a pro-
spective observational cohort study carried out on 72 kidney
transplant recipients, of which 23 received a living-donor trans-
plant (58 on dialysis before transplantation and 14 pre-emptive
transplant recipients), until 6 months after transplantation. The
pre-transplantation FGF23 level was the main predictor of urin-
ary phosphate excretion and serum phosphate levels in the
early post-transplantation period, whereas serum phosphate le-
vels in the sixth month were mainly inﬂuenced by PTH at that
time. In this study, FGF23 levels decreased within the reference
range in 50% of patients in the ﬁrst month after transplantation
and in 77% of patientswith pre-emptive transplants. Kidney func-
tion improvementwas associatedwith a reduction in FGF23 levels
after transplantation.
Prasad et al. [21] addressed this issue by analysing at 1, 3 and
12 months the post-transplantation changes in FGF23, iPTH and
phosphate levels in 63 ESRD patients who underwent living-
donor transplantation. FGF23 and phosphate levels remained
above the normal range in 36.5 and 27% of patients, respectively,
at 1 month, in 15.9 and 8%, respectively, at 3 months and in none
of the patients at 12months post-transplantation,while only 11%
of patients had persisting hyperparathyroidism 12 months post-
transplantation. The authors postulated that two factors were re-
sponsible for these results, i.e. the shorter dialysis vintage prior to
transplantation and the inclusion of only living-donor transplant-
ation in the study, as renal function andmineral metabolism nor-
malize relatively faster than in deceased-donor transplantation
[22]. In kidney transplant recipients, the pathogenesis underlying
the imbalance between PTHand FGF23 levels is probablymultifac-
torial, involving persisting bone abnormalities and the effects of
immunosuppressive therapy. Except for mycophenolate, im-
munosuppressive drugs stimulate FGF23 production, impair vita-
minDmetabolismandconsequently increase PTHproduction [23,
24]. Speculatively the clinical use of calcineurin inhibitors (CNIs)
that block calcineurin signalling may increase the susceptibility
to develop or may aggravate pre-existing hyperparathyroidism
in patients with reduced Klotho expression, such as in kidney
transplant recipients [13].Nevertheless, Prasad et al.demonstrated
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that FGF23 levels normalized and the prevalence of hyperpara-
thyroidismwas lower (when compared with deceased-donor kid-
ney recipients) at 12months after transplantation, even though all
living-donor kidney transplant recipients underwent immuno-
suppressive schedules, including steroids and CNIs. This is an im-
portant ﬁnding of this study, but unfortunately there are only a
few experimental studies on this speciﬁc issue, and the feasibility
of clinical evaluations is hampered by the inability to assess the
effects of the individual drugs, as they are always administered
in combination.
Furthermore, the authors showed that the percentage de-
crease in FGF23 and iPTH levels was signiﬁcantly associated dur-
ing the entire follow-up. This interesting ﬁnding conﬁrms the
close interplay existing between FGF23 and PTH and suggests a
substantial integrity/recovery of the receptor and signalling path-
ways in this cohort of living-donor kidney transplant recipients.
The study by Prasad et al. conﬁrms a faster and signiﬁcant re-
covery in terms of mineral and bone disorders within the ﬁrst
year after transplantation in living-donor kidney transplant reci-
pients when compared with deceased-donor kidney transplant
recipients, perhaps as a result of a less marked bone and PTH de-
rangement due to the shorter dialysis vintage (Figure 1).Normal-
ization of phosphate and FGF23 levels and the reduced
prevalence of hyperparathyroidism are likely to have an import-
ant impact on graft and patient survival through reduced pro-
gression of cardiovascular and bone disease and this needs to
be conﬁrmed in larger studies with a longer follow-up. Of note,
the recovery of hyperphosphatoninism and hypophosphataemia
seems particularly intriguing in living-donor kidney transplant
recipients.
Chronically elevated FGF23 levels may be considered ultim-
ately as a maladaptive process in patients with CKD, given the
strong associations between higher FGF23 levels and increased
risk of left ventricular hypertrophy, congestive heart failure,
CKD progression and death [4, 25, 26]. In a prospective study of
stable kidney transplant recipients, elevated FGF23 levels were
independently associated with an increased risk of cardiovascu-
lar and all-cause mortality and allograft loss [10, 27]. There are
several possible mechanisms that may explain this ﬁnding. In
vitro and in vivo studies have shown that 1,25-dihydroxyvitamin
D decreases T cell activation and proliferation and inhibits den-
dritic cell differentiation andmaturation, while its supplementa-
tionmay have beneﬁcial effects on chronic allograft nephropathy
[24]. FGF23-mediated suppression of 1,25-dihydroxyvitamin D is
one possible mechanism through which high FGF23 levels could
contribute to allograft loss. In kidney transplant recipients, phos-
phate depletion, in conjunction with high PTH levels, vitamin D
deﬁciency and chronic steroid use,might worsen skeletal demin-
eralization and contribute directly to fractures, which in turn
could increase the risk of mortality. High levels of FGF23 may im-
pair neutrophil recruitment, which could jeopardize antibacter-
ial defence [28]. Moreover, if chronically increased FGF23 levels
can directly stimulate FGF receptors in the kidneys and heart, in-
dependent of Klotho [29], FGF23 couldmimic the knowneffects of
FGF2 to induce glomerulosclerosis and cardiac hypertrophy and
thereby contribute directly to chronic allograft nephropathy
anddeath [30, 31, 32]. Finally, FGF23 is associatedwith endothelial
dysfunctionandatherosclerosis inpatientswithhigh, orevennor-
mal, serum phosphate levels [33, 34]. Post-transplant hypophos-
phataemia and hypercalcaemia were associated with calcium
and phosphate deposition in renal allografts [35], although
human studies have shown conﬂicting results on whether renal
calciﬁcation contributes to worse allograft outcomes.
The study of Prasad et al. conﬁrms once again that the post–
kidney transplant period should be considered a unique phase
in the natural history of disordered mineral metabolism asso-
ciated with CKD that requires dedicated investigation. In living-
donor kidney transplant recipients, faster normalization of
FGF23 and phosphate levels, in addition to a lower prevalence
of hyperparathyroidism, if conﬁrmed in larger studies, could be
one of the possible pathways towards better outcomes in liv-
ing-donor kidney transplant recipients.
Fig. 1. Trends of PTH, FGF23 and phosphate (P) levels at 1 year after renal transplantation in a well-functioning graft. Deceased kidney donors are shown with a solid line
while living kidney donors are shown with a dashed line.
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